期刊文献+

霉酚酸治疗药物监测在肾移植中的应用进展

原文传递
导出
摘要 目的:介绍霉酚酸(MPA)在肾移植中的治疗药物监测进展。方法:查阅近年来肾移植患者MPA治疗药物监测的相关临床研究以及其他文献,进行归纳总结。结果:MPA在肾移植患者体内曲线下面积(AUC)差异大。肾移植术后早期,维持AUC在30-60mg·L^-1·h可有效降低急性排斥的发生。同时服用环孢素、钙调磷酸酶抑制剂(CNI)减量以及糖皮质激素撤除的患者尤其应该进行治疗药物监测。结论:MPA治疗药物监测具有重要的临床意义。
作者 程晟 史丽敏
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2011年第6期490-492,共3页 Chinese Journal of Hospital Pharmacy
  • 相关文献

参考文献16

  • 1张春丽,蒋金根,朱同玉,陈璋璋.中国肾移植患者常用霉酚酸酯剂量下霉酚酸血浆浓度监测[J].中国临床医学,2007,14(4):541-544. 被引量:3
  • 2余自成,周佩军,王祥慧,徐达,陈冰,张伟霞,安国华,方洁.有限取样法估算中国成年肾移植受者霉酚酸血药浓度-时间曲线下面积[J].中国临床药理学杂志,2006,22(6):452-455. 被引量:7
  • 3周佩军,徐达,王祥慧,余自成,赵菊平.肾移植受者霉酚酸治疗药物监测[J].上海交通大学学报(医学版),2006,26(6):680-684. 被引量:11
  • 4Atcheson BA,Taylor PJ,Kirkpatrick CM,et al.Free myco-phenolic acid should be monitored in renal transplant recipientswith hypoalbuminemia. Therapeutic Drug Monitoring . 2004
  • 5RS Gastona,,B Kaplanb,T Shahc,et al.Fixed-or Controlled-Dose Mycophenolate Mofetil with Standard-or Reduced-DoseCalcineurin Inhibitors:The Opticept Trial. AmericanTransplantation . 2009
  • 6HJ Johnson,SK Swan,KL Heim-Duthoy,AJ Nicholls,I Tsina,T Tarnowski.The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clinical Pharmacology and Therapeutics . 1998
  • 7CE Staatz,SE Tett.Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clinical Pharmacokinetics . 2007
  • 8M Naesens,DR Kuypers,K Verbeke,Y Vanrenterghem.Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation . 2006
  • 9Smak Gregoor PJH,van Gelder T,Hesse CJ,et al.Myco-phenolic acid plasma concentrations in kidney allograft re-cipient with or with ont cyclosporine:a cross-sectionalstudy. Nephrology Dialysis Transplantation . 1999
  • 10DR Kuypers,M Naesens,S Vermeire,Y Vanrenterghem.The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152?T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clinical Pharmacology and Therapeutics . 2005

二级参考文献37

  • 1余自成,蔡卫民,徐达,王祥慧.高效液相色谱法测定人血浆中霉酚酸酯及其活性代谢物霉酚酸的浓度[J].药物分析杂志,2005,25(4):381-384. 被引量:9
  • 2Allson AC,Eugui EM.Immunosuppressive and other effects of mycophenolic acid and an ester prodrug,mycophenolate mofetil[J].Immunol Rev,1993,136:5-28.
  • 3Sievers TM,Rossi SJ,Ghobrial RM,et al.Mycophenolate mofetil[J].Pharmacotherapy,1997,17(6):1178-1197.
  • 4The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.A blinded,randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation[J].Transplantation,1996,61(7):1029-1037.
  • 5Cattaneo D,Gaspari F,Ferrari S,et al.Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients[J].Clin Transplant,2001,15(6):402-409.
  • 6Atcheson BA,Taylor PJ,Mudge DW,et al.Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant[J].Br J Clin Pharmacol,2005,59(3):271-280.
  • 7Shaw LM,Korecka M,Aradhye S,et al.Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable[J].J Clin Pharmacol,2000,40(6):624-633.
  • 8Bullingham RE,Nicholls A,Hale M.Pharmacokinetics of mycophenolate mofetil (RS61443):a short review[J].Transplant Proc,1996,28(2):925-929.
  • 9Bland JM,Altman DG.Statistical methods for assessing agreement between two methods of clinical measurement[J].Lancet,1986,1(8476):307-310.
  • 10Touw DJ,Neef C,Thomson AH,et al.Cost-Effectiveness of Therapeutic Drug Monitoring Committee of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology.Cost-effectiveness of therapeutic drug monitoring:a systematic review[J].Ther Drug Monit,2005,27(1):10-17.

共引文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部